The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

Approval of the topical aryl hydrocarbon receptor agonist was supported by the pivotal ADORING studies. In the ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals ...

China: A recent analysis from the National Health and Nutrition Examination Survey (NHANES) 2005–2006 revealed that ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

Doctors and researchers use the terms “eczema” and “atopic dermatitis” interchangeably. However, other types of dermatitis and eczema have more specific names, different symptoms ...

When 30-year-old Eve (not her real name) gave birth to her baby son, Luke (not his real name), in early 2024, she knew she ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) with or without asthma and allergic rhinitis in young children.

Atopic dermatitis in infancy is associated with an increased risk of developing subsequent atopic march conditions such as allergy or asthma.

When conventional treatments for moderate to severe atopic dermatitis become less effective, targeted therapies may help.

The FDA approved Vtama (tapinarof) cream 1% for treating atopic dermatitis (AD) in adults and children as young as ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis ...